About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker JAZZ · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237 · Maternal Complications, Pregnancy Complication
Epidiolex
JAZZ
Jazz Pharmaceuticals
—Recruiting50Aug 31, 2033Registry ↗
Nov 12, 2026A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclon…
NCT07723963 · Juvenile Myoclonic Epilepsy
JZP926 capsule, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 2/3Recruiting260Aug 1, 2028Registry ↗
Nov 9, 2026Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
NCT04541082 · Central Nervous System Neoplasms, Glioblastoma
ONC206
JAZZ
Jazz Pharmaceuticals
Phase 1Active, not recruiting
was recruiting
35Mar 31, 2027Registry ↗
Nov 6, 2026A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-S…
NCT07459634 · Extensive-stage Small-cell Lung Cancer
Lurbinectedin, Durvalumab
JAZZ
Jazz Pharmaceuticals
Phase 2Recruiting50Aug 4, 2029Registry ↗
Nov 5, 2026Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refracto…
NCT05734066 · Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma
Lurbinectedin
JAZZ
Jazz Pharmaceuticals
Phase 1/2Recruiting60Jan 28, 2028Registry ↗
Nov 4, 2026A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in H…
NCT07813663 · Healthy Participants
JZP269, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 1Recruiting
was not yet recruiting
212Feb 27, 2027Registry ↗
Nov 4, 2026A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845 · Breast Cancer, Gastric Cancer
Zanidatamab
JAZZ
Jazz Pharmaceuticals
Phase 2Recruiting200Dec 31, 2026Registry ↗
Nov 4, 2026A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing…
NCT03929666 · HER2-expressing Gastrointestinal Cancers, Including Gastroe…
ZW25 (Zanidatamab), Capecitabine
JAZZ
Jazz Pharmaceuticals
Phase 2Completed74Aug 30, 2025Registry ↗
Nov 3, 2026Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setti…
NCT05772429 · Seizures
Epidiolex
JAZZ
Jazz Pharmaceuticals
—Completed
was active, not recruiting
158Aug 25, 2026Registry ↗
Oct 29, 2026A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
NCT07533942 · Meningioma
JZP3507
JAZZ
Jazz Pharmaceuticals
Phase 2Recruiting30Oct 25, 2028Registry ↗
Oct 29, 2026Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
NCT07282587 · Advanced Pheochromocytoma and Paraganglioma, PCPG
ONC206, ONC206: Dose 1
JAZZ
Jazz Pharmaceuticals
Phase 2Recruiting90Dec 15, 2028Registry ↗
Oct 29, 2026A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP92…
NCT07233239 · Focal Seizures
CBD-OS
JAZZ
Jazz Pharmaceuticals
Phase 1Recruiting100Nov 29, 2027Registry ↗
Oct 29, 2026A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HE…
NCT07102381 · HER2-positive Breast Cancer, Breast Cancer
Zanidatamab, Paclitaxel
JAZZ
Jazz Pharmaceuticals
Phase 2Recruiting125Dec 29, 2027Registry ↗
Oct 28, 2026Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy f…
NCT06282575 · Biliary Tract Cancer
Zanidatamab, Cisplatin
JAZZ
Jazz Pharmaceuticals
Phase 3Recruiting286Dec 1, 2028Registry ↗
Oct 26, 2026Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
NCT07780968 · Esophageal Cancer, GastroEsophageal Cancer
Zanidatamab
JAZZ
Jazz Pharmaceuticals
—Not yet recruiting300Oct 1, 2031Registry ↗
Oct 23, 2026A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Hea…
NCT07377539 · Healthy Participants
JZP047, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 1Active, not recruiting86Nov 30, 2026Registry ↗
Oct 22, 2026A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults…
NCT07728097 · Lennox-Gastaut Syndrome
Cannabidiol Oral Solution
JAZZ
Jazz Pharmaceuticals
Phase 4Not yet recruiting40Dec 28, 2028Registry ↗
Oct 20, 2026A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With…
NCT05152147 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma
Zanidatamab, Tislelizumab
JAZZ
Jazz Pharmaceuticals
Phase 3Active, not recruiting920Jul 15, 2026Registry ↗
Oct 8, 2026A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With…
NCT07625280 · Narcolepsy, Idiopathic Hypersomnia
Xywav, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 3Recruiting120Dec 23, 2027Registry ↗
Sep 24, 2026Phase 2a Study of ZW25 in Combination With Palbociclib Plus Fulvestrant
NCT04224272 · HER2+/HR+ Breast Cancer
ZW25 (Zanidatamab), Palbociclib
JAZZ
Jazz Pharmaceuticals
Phase 2Completed51Apr 28, 2023Registry ↗
Sep 10, 2026A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harb…
NCT05557045 · Advanced Cancer, Metastatic Cancer
JZP815
JAZZ
Jazz Pharmaceuticals
Phase 1Active, not recruiting98Apr 1, 2028Registry ↗
Aug 27, 2026A Study to Investigate the Effect of XYWAV on Sleepiness, Polysomnography, and Functional Outcomes…
NCT05875974 · Idiopathic Hypersomnia, Narcolepsy
JZP258 (XYWAV)
JAZZ
Jazz Pharmaceuticals
Phase 4Completed199Mar 13, 2025Registry ↗
Aug 26, 2026Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidio…
NCT05044819 · Lennox Gastaut Syndrome, Dravet Syndrome
Cannabidiol
JAZZ
Jazz Pharmaceuticals
Phase 4Active, not recruiting154Aug 1, 2027Registry ↗
Jul 24, 2026A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
NCT07723976 · Developmental and Epileptic Encephalopathy (DEE)
CBD-OS, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 3Not yet recruiting120Sep 4, 2029Registry ↗
Jul 1, 2026A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Ca…
NCT05027139 · HER2-expressing Cancers
Zanidatamab, Evorpacept
JAZZ
Jazz Pharmaceuticals
Phase 1/2Completed52Aug 29, 2025Registry ↗
Jun 3, 2026Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Stud…
NCT05485831 · Lennox Gastaut Syndrome, Dravet Syndrome
Epidiolex 100 mg/mL Oral Solution
JAZZ
Jazz Pharmaceuticals
—Active, not recruiting111Feb 2027Registry ↗
Apr 27, 2026A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy…
NCT05864846 · Tuberous Sclerosis Complex Associated Neuropsychiatric Dise…
Cannabidiol Oral Solution [Epidiolex]
JAZZ
Jazz Pharmaceuticals
Phase 4Completed79Apr 6, 2026Registry ↗
Apr 24, 2026A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participa…
NCT05869773 · Narcolepsy
JZP258
JAZZ
Jazz Pharmaceuticals
Phase 4Completed155Feb 25, 2025Registry ↗
Apr 16, 2026ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562 · H3 K27M, Glioma
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo
JAZZ
Jazz Pharmaceuticals
Phase 3Recruiting510Jun 2028Registry ↗
Apr 6, 2026A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With…
NCT06961266 · Narcolepsy
JZP441, Matching Placebo
JAZZ
Jazz Pharmaceuticals
Phase 1Terminated6Jan 29, 2026Registry ↗
Feb 27, 2026To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cel…
NCT04894591 · Extensive-stage Small-cell Lung Cancer
Zepzelca
JAZZ
Jazz Pharmaceuticals
—Completed272Jun 4, 2025Registry ↗
Feb 10, 2026A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With P…
NCT06435429 · Metastatic HER2-positive Breast Cancer
Zanidatamab, Trastuzumab
JAZZ
Jazz Pharmaceuticals
Phase 3Recruiting550Apr 28, 2028Registry ↗
Jan 15, 2026A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
NCT05642442 · Parkinson Disease, Tremor
Placebo, Suvecaltamide
JAZZ
Jazz Pharmaceuticals
Phase 2Completed169Oct 23, 2024Registry ↗
Dec 16, 2025JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanc…
NCT06108050 · Advanced Solid Tumor, Metastatic Solid Tumor
JZP898, Pembrolizumab
JAZZ
Jazz Pharmaceuticals
Phase 1Recruiting177Nov 30, 2027Registry ↗
Nov 20, 2025VYxeoS Liposomal Italian Observational Study iN the Real Practice
NCT06143839 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With M…
Vyxeos liposomal
JAZZ
Jazz Pharmaceuticals
—Completed113Oct 23, 2025Registry ↗
Oct 31, 2025Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis…
NCT04485104 · Seizure in Participants With Tuberous Sclerosis Complex, Se…
GWP42003-P
JAZZ
Jazz Pharmaceuticals
Phase 3Terminated3Jan 28, 2025Registry ↗
Sep 15, 2025A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract…
NCT04466891 · HER2-amplified Biliary Tract Cancers
ZW25 (Zanidatamab)
JAZZ
Jazz Pharmaceuticals
Phase 2Completed87Jul 28, 2023Registry ↗
Aug 20, 2025Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
NCT04617002 · Glioma, H3 K27M
ONC201 (dordaviprone)
JAZZ
Jazz Pharmaceuticals
—Approved for marketing——Registry ↗
Jul 28, 2025ONC201 in Adults With Recurrent H3 K27M-mutant Glioma
NCT03295396 · Glioma
Dordaviprone (ONC201)
JAZZ
Jazz Pharmaceuticals
Phase 2Terminated73Dec 31, 2022Registry ↗
Jul 24, 2025A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Sev…
NCT05122650 · Essential Tremor
JZP385, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 2Completed420May 30, 2024Registry ↗
May 25, 2025An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced…
NCT04578444 · HER2-Positive Advanced Biliary Tract Cancer
Zanidatamab
JAZZ
Jazz Pharmaceuticals
—No longer available——Registry ↗
Mar 30, 2025Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in C…
NCT04745026 · Autism Spectrum Disorder
GWP42003-P, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 2Completed103Dec 21, 2023Registry ↗
Feb 28, 2025Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
NCT05126433 · Advanced Solid Tumor, Metastatic Solid Tumor
Lurbinectedin
JAZZ
Jazz Pharmaceuticals
Phase 2Terminated47Dec 20, 2023Registry ↗
Feb 14, 2025ONC201 in Pediatric H3 K27M Gliomas
NCT03416530 · Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
Dordaviprone (ONC201)
JAZZ
Jazz Pharmaceuticals
Phase 1Terminated134Dec 31, 2022Registry ↗
Feb 3, 2025Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Sei…
NCT05288283 · Seizures Associated With EMAS
GWP42003-P, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 3Terminated3Sep 28, 2023Registry ↗
Dec 31, 2024A Study of JZP150 in Adults With Posttraumatic Stress Disorder
NCT05178316 · Post Traumatic Stress Disorder
JZP150, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 2Completed282Dec 5, 2023Registry ↗
Dec 24, 2024ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
NCT03485729 · Endometrial Cancer Recurrent
Dordaviprone (ONC201)
JAZZ
Jazz Pharmaceuticals
Phase 2Terminated27Jan 19, 2023Registry ↗
Dec 24, 2024Oral ONC201 in Adult Recurrent Glioblastoma
NCT02525692 · Glioblastoma, Diffuse Midline Glioma
Dordaviprone (ONC201)
JAZZ
Jazz Pharmaceuticals
Phase 2Terminated84Apr 17, 2023Registry ↗
Dec 11, 2024Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Parti…
NCT04984278 · Spasticity With Multiple Sclerosis
Nabiximols, Placebo
JAZZ
Jazz Pharmaceuticals
Phase 3Terminated56Nov 11, 2022Registry ↗
Nov 27, 2024Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
NCT02892123 · HER2-expressing Cancers
ZW25 (Zanidatamab), Paclitaxel
JAZZ
Jazz Pharmaceuticals
Phase 1Completed279Oct 31, 2024Registry ↗

The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:13 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances